Narayana Hrudayalaya runs a multi-specialty hospital network across India, Cayman Islands and the UK, with primary-care clinics and a health insurance arm linked to the hospitals. The money is made primarily in Indian hospital operations, where cardiac still contributes about one-third of revenue and oncology is the fastest-growing service, expected to exceed 20% of revenue over time. India has not added hospital beds for seven to eight years, so growth has come from higher throughput, more complex procedures and payor mix improvement. That discipline pushed India hospital EBITDA margins from 21.5% in FY25 to 25.1% in FY26, and consolidated EBITDA reached 24% in Q1 FY27 with India net margin up 400 basis points year on year. The competitive field is fragmented, but Narayana holds strong cluster positions in Bangalore, Kolkata and Raipur, and its 66,000 quarterly clinic consultations, up 30%, feed both hospital footfall and insurance underwriting data.
These economics persist because of the integrated structure rather than any single asset. Narayana is the only hospital-promoted insurance company in India, giving it access to primary-care claims data that should improve underwriting as the book scales. Senior doctor attrition is low, in high single digits, and the low-cost, high-volume clinical model has consistently generated above-average margins. In the UK, the acquired hospital business is the fourth largest private provider, with all assets rated good or excellent by the regulator and a stable, inflation-linked NHS tariff base; its normalized EBITDA is 8.5-9% pre-IFRS, and management sees a path from roughly 95% NHS dependence toward peer levels of private payor mix. Barriers are real but not absolute: new competitors in Bangalore and Gurgaon have caused temporary volume shortfalls, and UK earnings still rely heavily on NHS contracts. Still, cluster scale, clinician retention and insurance-data advantages are difficult to replicate quickly.
The 18-24 month picture is one of delayed but meaningful capacity and continued margin climb from existing beds. The committed INR 3,000 crore capex is being deployed over two years into Rajarhat health city in Kolkata, a new tower in Raipur, and Bangalore expansions; some projects have slipped from FY28 to FY29-30 due to partner-licensing issues, so commissioning will be staggered. Southwest Bangalore's 100-bed hospital was committed to start by end of Q2 FY27, and the HSR expansion is on track. In the UK, software platform rollout has been delayed 4-6 months for certification, but the strategy remains to move private payor mix toward peer levels and target 20-22% ROCE by FY29-30. Cayman insurance, after July 2026 repricing with 100% renewal acceptance, is already reducing losses, and India insurance is expanding into Kolkata and Raipur in phases. By mid-to-late 2028, the company should have a larger India footprint, higher-margin matured hospitals, a UK business near EPS neutrality, and insurance losses contained to a smaller drag.
Management walk-talk has been mixed. India margins expanded 150-200 basis points in two consecutive quarters through FY26, beating the implied trajectory from the earlier FY26 guidance, and net debt to EBITDA is below 1x, well inside the 2.5-3x ceiling. But capacity timelines have slipped: Southwest Bangalore was guided to be about a year away in August 2025 and by February 2026 was still only in interiors and equipment; the Mumbai upgrade has not closed; and some projects moved from FY28 to FY29-30. Insurance losses were expected to narrow earlier but widened before the latest sequential improvement, while UK integration was hit by a heatwave causing 70 lost operating days in Q1 and regulatory certification delays. Management has stopped giving quantitative revenue or PAT guidance, but it has committed to INR 3,000 crore of capex, net debt to EBITDA below 2.5x, and UK EPS neutrality in year one. The scorecard is operational on margins, executionary on capacity and breakeven timelines.
The earnings path is visible: India core operating margin should keep expanding with no new beds opening for the next 2-3 years and average length of stay falling from 4.3 toward 3.9-4, while oncology and robotic procedures raise realisations. Cayman insurance losses fell from INR 5.2 million to INR 3.7 million sequentially, and the UK normalized EBITDA margin of 8.5-9% pre-IFRS should improve as private payor mix rises and technology takes out administrative cost. The key assumptions are that India insurance volatility does not worsen, UK certification and heatwave repairs do not push out benefits, and new hospitals begin filling beds by FY29 without prolonged dilution. The single most important falsifier is UK transformation: if NHS dependence stays above 90% and software deployment slips further, consolidated margin recovery will be delayed even though India continues to improve. That tension between rising India margins and consolidated drags is operational, not structural, because the drags are investments with explicit timelines. The business 18-24 months from now should have higher India margins, the first significant capacity addition in years just coming online, and a UK and insurance complex that has stopped diluting earnings.
companyname: Narayana Hrudayalaya Limited ticker: NH sector: Healthcare / Hospital & Healthcare Services Narayana Hrudayalaya Limited (NHL) is a multi-specialty healthcare provider founded in 2000 by cardiac surgeon Dr. Devi Prasad Shetty. The group operates 17 NABH-accredited hospitals in India, two hospitals in the Cayman Islands, and 12 elective-care hospitals in the UK acquired in November 2025. In FY26, consolidated operating revenue was ₹78,960 million, with 2.7 million outpatient consult...
Read the full report →capex, margin expansion
No guidance
Guidance no_datamixed
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Narayana Hrudayalaya Limited and 4,900+ companies.
5-day free pass. No card required.